_id
695fb56ac2e91020a7bd41ce
Ticker
0H19.LSE
Name
Orexo AB (publ)
Exchange
LSE
Address
Rapsgatan 7E, Uppsala, Sweden
Country
UK
Sector
Industry
Currency
SEK
Website
https://www.orexo.com
Description
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar, for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
Last Close
34.775
Volume
-
Current Price
34.775
Change
3.05
Last Updated
2026-01-08T13:47:22.712Z
Ipo Date
-
Market Cap
701753920
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2019-09-30
Revenue
231200000
Cost Of Revenue
25900000
Gross Profit
205300000
Operating Expenses
133600000
Operating Income
97600000
Interest Expense
-
Pretax Income
114700000
Net Income
111700000
Eps
-
Dividends Per Share
-
Shares Outstanding
34581300
Income Tax Expense
3000000
EBITDA
-
Operating Margin
42.21453287197232
Total Other Income Expense Net
17100000
Cash
812900000
Short Term Investments
-
Receivables
286400000
Inventories
137000000
Total Current Assets
1236400000
Property Plant Equipment
84000000
Total Assets
1545300000
Payables
-
Short Term Debt
-
Long Term Debt
289200000
Total Liabilities
873600000
Equity
671700000
Bs_currency_symbol
SEK
Depreciation
8200000
Change In Working Capital
-
Cash From Operations
135700000
Capital Expenditures
13700000
Cash From Investing
-14500000
Cash From Financing
-36900000
Net Change In Cash
115900000
Cf_currency_symbol
SEK
PE
-
PB
-
ROE
16.629447670090812
ROA
7.228369895813111
FCF
122000000
Fcf Percent
0.527681660899654
Piotroski FScore
4
Health Score
67
Deep Value Investing Score
4.5
Defensive Investing Score
4
Dividend Investing Score
3
Economic Moat Investing Score
10
Garp Investing Score
5
Growth Investing Score
4
Momentum Investing Score
4.5
Net Net Investing Score
5
Quality Investing Score
8.5
Value Investing Score
4
Quarters > 0 > quarter
2019-09-30
Quarters > 0 > income Statement > revenue
231200000
Quarters > 0 > income Statement > cost Of Revenue
25900000
Quarters > 0 > income Statement > gross Profit
205300000
Quarters > 0 > income Statement > operating Expenses
133600000
Quarters > 0 > income Statement > operating Income
97600000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
114700000
Quarters > 0 > income Statement > net Income
111700000
Quarters > 0 > income Statement > eps
-
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
-
Quarters > 0 > income Statement > income Tax Expense
3000000
Quarters > 0 > income Statement > EBITDA
-
Quarters > 0 > income Statement > operating Margin
42.21453287197232
Quarters > 0 > income Statement > total Other Income Expense Net
17100000
Quarters > 0 > income Statement > currency_symbol
SEK
Quarters > 0 > balance Sheet > cash
812900000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
286400000
Quarters > 0 > balance Sheet > inventories
137000000
Quarters > 0 > balance Sheet > total Current Assets
1236400000
Quarters > 0 > balance Sheet > property Plant Equipment
84000000
Quarters > 0 > balance Sheet > total Assets
1545300000
Quarters > 0 > balance Sheet > payables
-
Quarters > 0 > balance Sheet > short Term Debt
-
Quarters > 0 > balance Sheet > long Term Debt
289200000
Quarters > 0 > balance Sheet > total Liabilities
873600000
Quarters > 0 > balance Sheet > equity
671700000
Quarters > 0 > balance Sheet > currency_symbol
SEK
Quarters > 0 > cash Flow > net Income
111700000
Quarters > 0 > cash Flow > depreciation
8200000
Quarters > 0 > cash Flow > change In Working Capital
-
Quarters > 0 > cash Flow > cash From Operations
135700000
Quarters > 0 > cash Flow > capital Expenditures
13700000
Quarters > 0 > cash Flow > cash From Investing
-14500000
Quarters > 0 > cash Flow > cash From Financing
-36900000
Quarters > 0 > cash Flow > net Change In Cash
115900000
Quarters > 0 > cash Flow > currency_symbol
SEK
Quarters > 0 > ratios > PE
-
Quarters > 0 > ratios > PB
-
Quarters > 0 > ratios > ROE
16.629447670090812
Quarters > 0 > ratios > ROA
7.228369895813111
Quarters > 0 > ratios > FCF
122000000
Quarters > 0 > ratios > Piotroski FScore
4
Quarters > 0 > ratios > fcf Percent
0.527681660899654
Quarters > 0 > health Score
67
Quarters > 1 > quarter
2019-06-30
Quarters > 1 > income Statement > revenue
201200000
Quarters > 1 > income Statement > cost Of Revenue
31300000
Quarters > 1 > income Statement > gross Profit
169900000
Quarters > 1 > income Statement > operating Expenses
145200000
Quarters > 1 > income Statement > operating Income
56000000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
58500000
Quarters > 1 > income Statement > net Income
54600000
Quarters > 1 > income Statement > eps
-
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
-
Quarters > 1 > income Statement > income Tax Expense
3900000
Quarters > 1 > income Statement > EBITDA
-
Quarters > 1 > income Statement > operating Margin
27.833001988071572
Quarters > 1 > income Statement > total Other Income Expense Net
2500000
Quarters > 1 > income Statement > currency_symbol
SEK
Quarters > 1 > balance Sheet > cash
697000000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
291100000
Quarters > 1 > balance Sheet > inventories
150600000
Quarters > 1 > balance Sheet > total Current Assets
1138700000
Quarters > 1 > balance Sheet > property Plant Equipment
84900000
Quarters > 1 > balance Sheet > total Assets
1440100000
Quarters > 1 > balance Sheet > payables
-
Quarters > 1 > balance Sheet > short Term Debt
-
Quarters > 1 > balance Sheet > long Term Debt
321300000
Quarters > 1 > balance Sheet > total Liabilities
887200000
Quarters > 1 > balance Sheet > equity
552900000
Quarters > 1 > balance Sheet > currency_symbol
SEK
Quarters > 1 > cash Flow > net Income
54600000
Quarters > 1 > cash Flow > depreciation
7600000
Quarters > 1 > cash Flow > change In Working Capital
-
Quarters > 1 > cash Flow > cash From Operations
46100000
Quarters > 1 > cash Flow > capital Expenditures
800000
Quarters > 1 > cash Flow > cash From Investing
-800000
Quarters > 1 > cash Flow > cash From Financing
-3800000
Quarters > 1 > cash Flow > net Change In Cash
49600000
Quarters > 1 > cash Flow > currency_symbol
SEK
Quarters > 1 > ratios > PE
-
Quarters > 1 > ratios > PB
-
Quarters > 1 > ratios > ROE
9.875203472599022
Quarters > 1 > ratios > ROA
3.7914033747656415
Quarters > 1 > ratios > FCF
45300000
Quarters > 1 > ratios > Piotroski FScore
3
Quarters > 1 > ratios > fcf Percent
0.22514910536779323
Quarters > 1 > health Score
57
Quarters > 2 > quarter
2019-03-31
Quarters > 2 > income Statement > revenue
174300000
Quarters > 2 > income Statement > cost Of Revenue
25300000
Quarters > 2 > income Statement > gross Profit
149000000
Quarters > 2 > income Statement > operating Expenses
131400000
Quarters > 2 > income Statement > operating Income
42900000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
5900000
Quarters > 2 > income Statement > net Income
14100000
Quarters > 2 > income Statement > eps
-
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
-
Quarters > 2 > income Statement > income Tax Expense
-8200000
Quarters > 2 > income Statement > EBITDA
-
Quarters > 2 > income Statement > operating Margin
24.612736660929432
Quarters > 2 > income Statement > total Other Income Expense Net
-37000000
Quarters > 2 > income Statement > currency_symbol
SEK
Quarters > 2 > balance Sheet > cash
647400000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
252200000
Quarters > 2 > balance Sheet > inventories
166400000
Quarters > 2 > balance Sheet > total Current Assets
1065900000
Quarters > 2 > balance Sheet > property Plant Equipment
87700000
Quarters > 2 > balance Sheet > total Assets
1367400000
Quarters > 2 > balance Sheet > payables
-
Quarters > 2 > balance Sheet > short Term Debt
-
Quarters > 2 > balance Sheet > long Term Debt
321000000
Quarters > 2 > balance Sheet > total Liabilities
870800000
Quarters > 2 > balance Sheet > equity
496600000
Quarters > 2 > balance Sheet > currency_symbol
SEK
Quarters > 2 > cash Flow > net Income
14100000
Quarters > 2 > cash Flow > depreciation
10900000
Quarters > 2 > cash Flow > change In Working Capital
-
Quarters > 2 > cash Flow > cash From Operations
50900000
Quarters > 2 > cash Flow > capital Expenditures
100000
Quarters > 2 > cash Flow > cash From Investing
100000
Quarters > 2 > cash Flow > cash From Financing
-10700000
Quarters > 2 > cash Flow > net Change In Cash
57600000
Quarters > 2 > cash Flow > currency_symbol
SEK
Quarters > 2 > ratios > PE
-
Quarters > 2 > ratios > PB
-
Quarters > 2 > ratios > ROE
2.83930728956907
Quarters > 2 > ratios > ROA
1.031154014918824
Quarters > 2 > ratios > FCF
50800000
Quarters > 2 > ratios > Piotroski FScore
4
Quarters > 2 > ratios > fcf Percent
0.291451520367183
Quarters > 2 > health Score
50
Quarters > 3 > quarter
2018-12-31
Quarters > 3 > income Statement > revenue
227100000
Quarters > 3 > income Statement > cost Of Revenue
43400000
Quarters > 3 > income Statement > gross Profit
183700000
Quarters > 3 > income Statement > operating Expenses
195800000
Quarters > 3 > income Statement > operating Income
31300000
Quarters > 3 > income Statement > interest Expense
11700000
Quarters > 3 > income Statement > pretax Income
37200000
Quarters > 3 > income Statement > net Income
51500000
Quarters > 3 > income Statement > eps
-
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
-
Quarters > 3 > income Statement > income Tax Expense
-14300000
Quarters > 3 > income Statement > EBITDA
-
Quarters > 3 > income Statement > operating Margin
13.782474680757376
Quarters > 3 > income Statement > total Other Income Expense Net
-20500000
Quarters > 3 > income Statement > currency_symbol
SEK
Quarters > 3 > balance Sheet > cash
589800000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
292000000
Quarters > 3 > balance Sheet > inventories
173600000
Quarters > 3 > balance Sheet > total Current Assets
1059500000
Quarters > 3 > balance Sheet > property Plant Equipment
20000000
Quarters > 3 > balance Sheet > total Assets
1286700000
Quarters > 3 > balance Sheet > payables
47700000
Quarters > 3 > balance Sheet > short Term Debt
-
Quarters > 3 > balance Sheet > long Term Debt
320600000
Quarters > 3 > balance Sheet > total Liabilities
810600000
Quarters > 3 > balance Sheet > equity
476100000
Quarters > 3 > balance Sheet > currency_symbol
SEK
Quarters > 3 > cash Flow > net Income
51500000
Quarters > 3 > cash Flow > depreciation
5300000
Quarters > 3 > cash Flow > change In Working Capital
-
Quarters > 3 > cash Flow > cash From Operations
71600000
Quarters > 3 > cash Flow > capital Expenditures
700000
Quarters > 3 > cash Flow > cash From Investing
-4000000
Quarters > 3 > cash Flow > cash From Financing
-10700000
Quarters > 3 > cash Flow > net Change In Cash
73200000
Quarters > 3 > cash Flow > currency_symbol
SEK
Quarters > 3 > ratios > PE
-
Quarters > 3 > ratios > PB
-
Quarters > 3 > ratios > ROE
10.817055240495694
Quarters > 3 > ratios > ROA
4.002486982202534
Quarters > 3 > ratios > FCF
70900000
Quarters > 3 > ratios > Piotroski FScore
4
Quarters > 3 > ratios > fcf Percent
0.31219726992514313
Quarters > 3 > health Score
59
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > metrics > ROE
16.629447670090812
Profitability > metrics > ROA
9.034293109026205
Profitability > metrics > Net Margin
0.48313148788927335
Profitability > final Score
90
Profitability > verdict
Adequate
Risk > metrics > Debt Equity
1.3005806163465834
Risk > metrics > Interest Coverage
5.707602339181286
Risk > final Score
53
Risk > verdict
High
Liquidity > final Score
50
Liquidity > verdict
Weak
Prev Valuations > 0
50
Prev Valuations > 1
50
Prev Valuations > 2
50
Prev Profitabilities > 0
64
Prev Profitabilities > 1
22
Prev Profitabilities > 2
66
Prev Risks > 0
70
Prev Risks > 1
35
Prev Risks > 2
41
Prev Liquidities > 0
50
Prev Liquidities > 1
50
Prev Liquidities > 2
100
Updated At
2026-01-20T23:13:26.184Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-02-05
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
AfterMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-0.3
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar, for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
Stock Price
SEK0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2019-09-30)
Health Score
Return on Equity (ROE)
-
Medium
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
High
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very High
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Orexo AB (publ)
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
-0.3
Date
—
EPS Actual
—
EPS Estimate
—
EPS Difference
—
Surprise Percent
undefined%
(Last Updated 2019-09-30)
(Last Updated 2019-09-30)
Revenue
SEK 0
Cost Of Revenue
SEK 0
Gross Profit
SEK 0
Operating Expenses
SEK 0
Operating Income
SEK 0
Interest Expense
SEK 0
Pretax Income
SEK 0
Net Income
SEK 0
Income Tax Expense
SEK 0
EBITDA
SEK 0
Total Other Income Expense Net
SEK 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2019-09-30)
Cash
SEK 0
Short Term Investments
SEK 0
Receivables
SEK 0
Inventories
SEK 0
Total Current Assets
SEK 0
Property Plant Equipment
SEK 0
Total Assets
SEK 0
Payables
SEK 0
Short Term Debt
SEK 0
Long Term Debt
SEK 0
Total Liabilities
SEK 0
Equity
SEK 0
(Last Updated 2019-09-30)
Net Income
SEK 0
Depreciation
SEK 0
Change In Working Capital
SEK 0
Cash From Operations
SEK 0
Capital Expenditures
SEK 0
Cash From Investing
SEK 0
Cash From Financing
SEK 0
Net Change In Cash
SEK 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.